Predicted protein targets (top 2)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CRBN | Q96SW2 | 3/20 | 0.36 |
| ▸ | TTR | P02766 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14713434 | 0.93 | CRBN (0.33) | CRBN | |
| SCHEMBL29444978 | 0.93 | CRBN (0.33) | CRBN | |
| SCHEMBL29521618 | 0.93 | CRBN (0.33) | CRBN | |
| SCHEMBL17319197 | 0.93 | CRBN (0.33) | CRBN | |
| SCHEMBL19725973 | 0.93 | CRBN (0.33) | CRBN | |
| SCHEMBL23194379 | 0.93 | CRBN (0.33) | CRBN | |
| SCHEMBL14981499 | 0.93 | CRBN (0.33) | CRBN | |
| SCHEMBL16329452 | 0.93 | CRBN (0.33) | CRBN | |
| SCHEMBL22657962 | 0.93 | CRBN (0.33) | CRBN | |
| SCHEMBL16329449 | 0.91 | GAA (0.33) | CRBN |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230364262-A1 | VIA CYCLOADDITION BILATERALLY FUNCTIONALIZED ANTIBODIES | SYNAFFIX B.V. (NL) | 2023-11-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230364262-A1 | VIA CYCLOADDITION BILATERALLY FUNCTIONALIZED ANTIBODIES | FCGR1A, FCGR3B, FCGR2A | CRBN 406/4885TTR 4841/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.